Earnings summaries and quarterly performance for PRECIGEN.
Executive leadership at PRECIGEN.
Board of directors at PRECIGEN.
Research analysts who have asked questions during PRECIGEN earnings calls.
Jennifer Kim
Cantor Fitzgerald
4 questions for PGEN
Also covers: BLTE, CPRX, EYPT +1 more
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
4 questions for PGEN
Also covers: ABSI, BSEM, CGEN +24 more
BB
Benjamin Burnett
Stifel, Nicolaus & Company, Incorporated
3 questions for PGEN
Also covers: IOVA, RVMD
BC
Brian Cheng
JPMorgan Chase & Co.
3 questions for PGEN
Also covers: ALLO, CHRS, EDIT +6 more
JB
Jason Butler
JMP Citizens
3 questions for PGEN
Also covers: ACAD, AQST, ATHA +9 more
LM
Lut Ming Cheng
JPMorgan Chase & Co.
2 questions for PGEN
Also covers: ALLO, CHRS, EDIT +3 more
Recent press releases and 8-K filings for PGEN.
Precigen's PAPZIMEOS Recommended as New Standard of Care for Adult RRP
PGEN
Product Launch
- A new expert consensus paper, published in The Laryngoscope, recommends Precigen's PAPZIMEOS (zopapogene imadenovec) as the new standard of care first-line treatment for adults with Recurrent Respiratory Papillomatosis (RRP).
- This recommendation signifies a shift in RRP management, moving from repeated surgical interventions towards an HPV-specific immunotherapy.
- PAPZIMEOS is the first and only FDA-approved therapy designed to address the underlying cause of RRP in adults.
Jan 20, 2026, 1:05 PM
Precigen discusses Pepcimeus launch and financial outlook at J.P. Morgan Healthcare Conference
PGEN
Product Launch
Guidance Update
New Projects/Investments
- Precigen announced the full FDA approval of Pepcimeus in August 2025 for recurrent respiratory papillomatosis (RRP) and its subsequent U.S. commercial launch.
- The commercial launch of Pepcimeus has demonstrated strong early traction, achieving 96% coverage of target centers within three months, with over 50 accounts prescribing and approximately 80% of the target market (170 million lives) covered by payers.
- The company secured up to $125 million in non-dilutive funding and projects becoming cash flow positive by the end of 2026, driven by Pepcimeus revenues.
- Precigen is pursuing international regulatory expansion for Pepcimeus, with an EMA submission under review and planned submissions for Japan and a pediatric indication.
Jan 15, 2026, 3:30 PM
Precigen Achieves Commercial Stage with FDA Approval and Launch of PAPZIMEOS
PGEN
Product Launch
New Projects/Investments
- Precigen became a commercial-stage biopharmaceutical company in 2025, following the full FDA approval and commercial US launch of PAPZIMEOS for adults with Recurrent Respiratory Papillomatosis (RRP).
- PAPZIMEOS is the first-and-only FDA-approved treatment for RRP, targeting the underlying cause of the disease, and demonstrated a 51% Complete Response Rate in clinical data.
- In 2025, the company also recorded its first commercial sale of PAPZIMEOS and secured up to $125 million in non-dilutive funding.
Jan 15, 2026, 3:30 PM
Precigen Provides Update on Pepcimeus Commercialization and 2026 Cash Flow Positive Target
PGEN
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- Precigen received full FDA approval for Pepcimeus in August 2025 for recurrent respiratory papillomatosis (RRP) and has commenced its U.S. commercial launch.
- The company has secured up to $125 million in non-dilutive funding and anticipates becoming cash flow positive by the end of 2026.
- The commercial launch of Pepcimeus shows strong early indicators, with over 96% of target centers covered and approximately 170 million lives covered by payers within a quarter and a half of launch.
- Precigen is expanding Pepcimeus internationally with an EMA application under review for the EU and plans for Japan submission, while also advancing its adenovirus platform with two Phase II programs for HPV-related cancers.
Jan 15, 2026, 3:30 PM
Precigen Announces Full FDA Approval and Successful Commercial Launch of Pepcimeus
PGEN
Product Launch
Guidance Update
New Projects/Investments
- Precigen's drug, Pepcimeus, received full FDA approval in August 2025 for recurrent respiratory papillomatosis (RRP), becoming the first and only FDA-approved therapy for the condition.
- The U.S. commercial launch of Pepcimeus has commenced, with over 96% of target centers covered and more than 50 accounts prescribing the drug within three months of approval.
- Payer coverage for Pepcimeus has rapidly expanded to over 170 million lives, including Medicare, Medicaid, and private insurers, covering approximately 80% of the target market.
- The company anticipates becoming cash flow positive by the end of 2026, supported by existing cash and Pepcimeus revenues.
- Precigen is expanding Pepcimeus's regulatory reach with an EMA application under review and plans for Japan submission and pediatric studies, while also advancing two Phase 2 programs for HPV-related cancers using its adenovirus platform.
Jan 15, 2026, 3:30 PM
Precigen Provides Update on PAPZIMEOS Commercialization Momentum
PGEN
Product Launch
Guidance Update
New Projects/Investments
- Precigen has transitioned to a commercial-stage company following the US FDA approval of PAPZIMEOS in August 2025 for adults with Recurrent Respiratory Papillomatosis (RRP), with the therapy now being prescribed nationwide.
- Commercialization efforts show strong momentum, with over 200 patients registered in the PAPZIMEOS patient hub, doubling since November, and 96% of target centers engaged by the sales team.
- Patient access is expanding rapidly, with private health plan coverage now reaching approximately 170 million US lives, alongside coverage from Medicare and Medicaid.
- The European Medicines Agency has validated the Marketing Authorization Application for PAPZIMEOS, indicating progress towards international market expansion.
- Precigen expects its current capital resources to fund operations through cash flow break-even.
Jan 12, 2026, 1:00 PM
Precigen Reports Q3 2025 Results and PAPZIMEOS Commercial Launch Progress
PGEN
Earnings
Product Launch
Guidance Update
- Precigen announced the FDA approval of PAPZIMEOS in August 2025, marking its transition to a commercial-stage company. PAPZIMEOS is the first and only available treatment for adults with recurrent respiratory papillomatosis (RRP), demonstrating a 51% complete response rate and an 86% reduction in surgical burden.
- Commercial launch efforts for PAPZIMEOS are progressing, with the sales team deployed in September and the drug shipping to prescribers. The company has engaged 90% of target institutions, registered over 100 patients in its services hub, and achieved payer coverage for over 80 million lives as of last week.
- As of September 30, 2025, Precigen had $123.6 million in cash, cash equivalents, and investments. The company expects to fund its operations to cash flow breakeven by the end of 2026, utilizing current cash and projected PAPZIMEOS revenues.
- Precigen is also pursuing geographic expansion for PAPZIMEOS, having submitted a marketing authorization application with the EMA, and plans to initiate a clinical trial for the pediatric RRP population.
Nov 13, 2025, 9:30 PM
Precigen Reports Q3 2025 Financial Results and PAPZIMEOS Launch Update
PGEN
Earnings
Product Launch
Convertible Preferred Issuance
- Precigen announced the successful commercial launch of PAPZIMEOS (zopapogene imadenovec-drba), the first and only FDA-approved treatment for adults with Recurrent Respiratory Papillomatosis (RRP), following its full approval in August 2025. The product is now available and shipping in the US, with over 100 patients registered in the PAPZIMEOS Patient Hub and more than 100 million lives covered by private health insurance, in addition to Medicare and Medicaid availability.
- As of September 30, 2025, the company's cash, cash equivalents, and investments totaled $123.6 million, which is expected to fund operations to cash flow break-even. In September 2025, Precigen also secured a $125 million non-dilutive credit facility, receiving the first $100 million tranche.
- For the third quarter of 2025, Precigen reported a net loss attributable to common shareholders of $325.3 million, or $(1.06) per basic and diluted share. This loss was significantly impacted by non-cash items, including a $111.5 million increase in the fair value of warrant liabilities and a $179.0 million non-cash deemed dividend on preferred stock. Total revenues increased by $2.0 million compared to the three months ended September 30, 2024.
Nov 13, 2025, 9:18 PM
Precigen Reports Q3 2025 Financial Results and PAPZIMEOS Launch Updates
PGEN
Earnings
Product Launch
New Projects/Investments
- Precigen's PAPZIMEOS received full FDA approval in August 2025 and has launched in the US for adults with RRP, with over 100 patients registered in the Patient Hub and over 100 million lives covered by private health insurance.
- The company submitted a Marketing Authorization Application to the European Medicines Agency for PAPZIMEOS in November 2025.
- As of September 30, 2025, cash, cash equivalents, and investments totaled $123.6 million, which is expected to fund operations to cash flow break-even, supplemented by a $100 million first tranche from a new credit facility entered into in September 2025.
- For the third quarter of 2025, Precigen reported total revenues of $2.922 million and a net loss attributable to common shareholders of $325.3 million, or $(1.06) per basic and diluted share.
Nov 13, 2025, 9:05 PM
Precigen Announces Durable Long-Term Results for PAPZIMEOS in RRP
PGEN
Product Launch
New Projects/Investments
- Precigen (PGEN) announced long-term follow-up data for PAPZIMEOS™ (zopapogene imadenovec-drba), the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), which received full approval in August 2025.
- The data, as of September 19, 2025, showed that 83% (15 out of 18) of complete responders maintained ongoing complete responses with a median follow-up of 36 months.
- A significant reduction in surgeries compared to pre-treatment was observed in 86% of patients in Year 1, 91% in Year 2, and 95% in Year 3, with no new safety events reported during long-term follow-up.
Oct 13, 2025, 11:00 AM
Quarterly earnings call transcripts for PRECIGEN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more